Pancreatic cancer remains among the malignancies with the worst outcomes. Survival has
been improving, but at a slower rate than other cancers. Multimodal treatment, including …

Objective: The objective of this study was to assess the association of survival with
neoadjuvant chemotherapy (NAC) in resectable pancreatic adenocarcinoma (PDAC) …

Background The rate of patients with pancreatic ductal adenocarcinoma (PDAC) receiving
neoadjuvant chemotherapy is increasing, but upfront resection is still offered to most patients …

Background A multimodal approach of surgery and chemotherapy, with or without radiation,
is the mainstay of therapy with curative-intent for resectable pancreatic ductal …

Background: Upfront resection (UR) followed by adjuvant chemotherapy remains the
standard treatment for resectable pancreatic cancer. There is increasing evidence …

Objectives We used a novel combined analysis to evaluate various factors associated with
failure to undergo surgery in non-metastatic pancreatic cancer. Methods We identified rates …

Background In contrast to pancreatic ductal adenocarcinoma (PDAC), neoadjuvant therapy
(NAT) for periampullary adenocarcinomas is not well studied, with data limited to single …

Three recent advances in the surgical approach to pancreatic cancer over the past decade
have improved both shortand long-term outcomes for patients with nonmetastatic, operable …

Aim: Chemotherapy is standard before and/or after pancreatic cancer resection, yet benefits
of pre-resection chemotherapy are unclear. Real-world pre-and post-resection treatment …

Abstract Background Return to Intended Oncologic Treatment (RIOT) has been proposed as
a quality metric in the care of cancer patients. We sought to define factors associated with …